Company's annual revenue growth of 17.16% outperformed its 3 year CAGR of 11.83%. (Source: Standalone Financials)
Loading...
Onyx Biotec Share Price
Advertisment
Onyx Biotec share price insights
Company has spent 3.2% of its operating revenues towards interest expenses and 13.95% towards employee cost in the year ending Mar 31, 2025. (Source: Standalone Financials)
Onyx Biotec Ltd. share price moved down by -4.63% from its previous close of Rs 51.90. Onyx Biotec Ltd. stock last traded price is 49.50
Share Price Value Today/Current/Last 49.50 Previous Day 51.90
Key Metrics
PE Ratio (x) | 0.00 | ||||||||||
EPS - TTM (₹) | 0.00 | ||||||||||
MCap (₹ Cr.) | 94.11 | ||||||||||
Sectoral MCap Rank | 447 | ||||||||||
PB Ratio (x) | 3.55 | ||||||||||
Div Yield (%) | 0.00 | ||||||||||
Face Value (₹) | 10.00 | ||||||||||
Beta Beta
| - | ||||||||||
VWAP (₹) | 51.16 | ||||||||||
52W H/L (₹) |
Onyx Biotec Share Price Returns
| 1 Day | -4.63% |
| 1 Week | -2.37% |
| 1 Month | -2.94% |
| 3 Months | N.A. |
| 1 Year | N.A. |
| 3 Years | N.A. |
| 5 Years | N.A. |
Onyx Biotec Share Analysis
Unlock Stock Score, Analyst' Ratings & Recommendations
- View Stock Score on a 10-point scale
- See ratings on Earning, Fundamentals, Valuation, Risk & Price
- Check stock performance
JOIN ET PRIME
Onyx Biotec Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
Onyx Biotec Financials
Insights
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 17.16% outperformed its 3 year CAGR of 11.83%. (Source: Standalone Financials)Employee & Interest Expense
Company has spent 3.2% of its operating revenues towards interest expenses and 13.95% towards employee cost in the year ending Mar 31, 2025. (Source: Standalone Financials)
Annual FY 2025 FY 2024 FY 2023 Total Revenue 63.12 53.87 39.62 Total Revenue Growth (%) 17.16 35.99 -11.93 Total Expenses 56.64 49.82 37.07 Total Expenses Growth (%) 13.68 34.40 -9.99 Profit after Tax (PAT) 4.95 3.03 1.84 PAT Growth (%) 63.42 64.35 -44.98 Operating Profit Margin (%) 13.66 11.45 7.85 Net Profit Margin (%) 7.99 5.64 4.67 Basic EPS (₹) 3.30 2.54 1.56 Annual FY 2025 FY 2024 FY 2023 Total Assets 91.25 74.14 58.72 Total Assets Growth (%) 23.08 26.26 59.39 Total Liabilities 35.63 49.26 40.52 Total Liabilities Growth (%) -27.67 21.57 98.04 Total Equity 55.62 24.88 18.20 Total Equity Growth (%) 123.55 36.70 11.11 Current Ratio (x) 1.91 1.31 0.72 Total Debt to Equity (x) 0.22 1.24 1.61 Contingent Liabilities 0.00 - - All figures in Rs Cr, unless mentioned otherwise
Insights
Cash from Operations vs PAT
Operating cash flow of Rs 1.42 cr is 0.29 times compared to the reported net profit of Rs 4.95 cr. (Source: Standalone Financials)
Annual FY 2025 FY 2024 FY 2023 Net Cash flow from Operating Activities 1.42 1.52 1.95 Net Cash used in Investing Activities 0.66 -3.15 -22.67 Net Cash flow from Financing Activities 5.07 3.09 16.43 Net Cash Flow 7.15 1.46 -4.29 Closing Cash & Cash Equivalent 8.61 1.47 -4.28 Closing Cash & Cash Equivalent Growth (%) 487.14 -134.30 0.00 Total Debt/ CFO (x) 8.79 20.30 14.97 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2025 FY 2024 FY 2023 Return on Equity (%) 8.90 12.18 10.13 Return on Capital Employed (%) 12.91 11.95 8.05 Return on Assets (%) 5.42 4.08 3.14 Interest Coverage Ratio (x) 5.80 3.99 8.28 Asset Turnover Ratio (x) 0.75 0.81 0.83 Price to Earnings (x) 21.23 - - Price to Book (x) 1.89 - - EV/EBITDA (x) 9.47 - - EBITDA Margin (%) 18.58 15.64 11.63
Onyx Biotec Technicals
Stock doesn't have any Buy/Sell Signals.
Price Analysis Data details are not available.
Pivot Levels
R1 R2 R3 PIVOT S1 S2 S3 Classic - - - - - - - Average True Range
5 DAYS 14 DAYS 28 DAYS ATR - - -
Onyx Biotec Peer Comparison
Choose from Peers
Choose from Stocks
- There’s no suggested peer for this stock.
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Loading...- See All Parameters
Onyx Biotec MF Ownership
MF Ownership details are not available.
Onyx Biotec Corporate Actions
Meeting Date Announced on Purpose Details May 28, 2025 May 26, 2025 Board Meeting Audited Results Jan 10, 2025 Jan 06, 2025 Board Meeting Quarterly Results Dividend announcements are not available.
No other corporate actions details are available.
About Onyx Biotec
Executives
Auditors
- SJ
Sanjay Jain
Managing DirectorHMHarsh Mahajan
Whole-time Director & CFO & CEOLJLakshya Jain
Whole Time DirectorNKNaresh Kumar
Whole Time DirectorShow More - RCA & Co. LLP
Industry
Key Indices Listed on
Nifty SME Emerge,
Address
Bir Plassi Near Sainimajraropar, Nalagarh Road,Solan District, Himachal Pradesh - 174101
More Details
Trending in Markets
Top Gainers As on 03:59 PM | 13 Jun 2025
Top Losers As on 03:57 PM | 13 Jun 2025
Onyx Biotec Quick Links
Equity Quick Links
More from Markets
IPOStock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.
